Yesterday, Dec. 22, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $102.00 to $44,180,000.00.

Highlighted Stocks Traded by Insiders:

Salesforce.com (CRM) - FREE Research Report

Roos John Victor, who is Director at Salesforce.com, sold 267 shares at $77.52 on Dec. 22, 2015. Following this transaction, the Director owned 19,947 shares meaning that the stake was reduced by 1.32% with the 267-share transaction.

The shares most recently traded at $78.79, up $1.27, or 1.61% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 266,789
  • 12-Week # shares sold: 715,552
  • 24-Week # shares sold: 723,908

The average volume for Salesforce.com has been 3.7 million shares per day over the past 30 days. Salesforce.com has a market cap of $51.3 billion and is part of the technology sector and computer software & services industry. Shares are up 31.28% year-to-date as of the close of trading on Tuesday.

salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship management to various businesses and industries worldwide. Currently, there are 29 analysts who rate Salesforce.com a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings

rates Salesforce.com as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and weak operating cash flow. Get the full

Salesforce.com Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

PartnerRe (PRE) - FREE Research Report

Desmet Laurie, who is EVP & COO, PartnerRe Ltd at PartnerRe, sold 710 shares at $139.11 on Dec. 22, 2015. Following this transaction, the EVP & COO, PartnerRe Ltd owned 38,386 shares meaning that the stake was reduced by 1.82% with the 710-share transaction.

The shares most recently traded at $139.40, up $0.29, or 0.21% since the insider transaction. Historical insider transactions for PartnerRe go as follows:

  • 4-Week # shares sold: 2,336
  • 12-Week # shares sold: 2,336
  • 24-Week # shares sold: 5,988

The average volume for PartnerRe has been 311,900 shares per day over the past 30 days. PartnerRe has a market cap of $6.7 billion and is part of the financial sector and insurance industry. Shares are up 22.01% year-to-date as of the close of trading on Tuesday.

PartnerRe Ltd., through its subsidiaries, provides reinsurance and certain specialty insurance services worldwide. It operates in three segments: Non-life, Life and Health, and Corporate and Other. The stock currently has a dividend yield of 2.01%. The company has a P/E ratio of 48.9. Currently, there are no analysts who rate PartnerRe a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PRE - FREE

TheStreet Quant Ratings

rates PartnerRe as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

PartnerRe Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and (LLY) - FREE Research Report

Lilly Endowment Inc, who is 10% Owner at Eli Lilly and, sold 205,000 shares at $86.00 on Dec. 22, 2015. Following this transaction, the 10% Owner owned 127.9 million shares meaning that the stake was reduced by 0.16% with the 205,000-share transaction.

The shares most recently traded at $86.52, up $0.52, or 0.6% since the insider transaction. Historical insider transactions for Eli Lilly and go as follows:

  • 4-Week # shares bought: 17,157
  • 4-Week # shares sold: 450,000
  • 12-Week # shares bought: 17,157
  • 12-Week # shares sold: 1.3 million
  • 24-Week # shares bought: 17,157
  • 24-Week # shares sold: 1.6 million

The average volume for Eli Lilly and has been 5.4 million shares per day over the past 30 days. Eli Lilly and has a market cap of $95.3 billion and is part of the health care sector and drugs industry. Shares are up 24.53% year-to-date as of the close of trading on Tuesday.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The stock currently has a dividend yield of 2.37%. The company has a P/E ratio of 38.8. Currently, there are 9 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLY - FREE

TheStreet Quant Ratings

rates Eli Lilly and as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Eli Lilly and Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.